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Human pluripotent stem cells (hPSCs) represent a
promising source of patient-specific cells for disease
modeling, drug screens, and cellular therapies. How-
ever, the inability to derive engraftable human he-
matopoietic stem and progenitor cells (HSPCs) has
limited their characterization to in vitro assays. We
report a strategy to respecify lineage-restricted
CD34+CD45+ myeloid precursors derived from
hPSCs into multilineage progenitors that can be
expanded in vitro and engrafted in vivo. HOXA9,
ERG, and RORA conferred self-renewal and multili-
neage potential in vitro and maintained primitive
CD34+CD38 cells. Screening cells via transplanta-
tion revealed that two additional factors, SOX4 and
MYB, conferred engraftment. Progenitors specified
with all five factors gave rise to reproducible short-
term engraftment with myeloid and erythroid line-
ages. Erythroid precursors underwent hemoglobin
switching in vivo, silencing embryonic and activating
adult globin expression. Our combinatorial screening
approach establishes a strategy for obtaining tran-
scription-factor-mediated engraftment of blood pro-
genitors from human pluripotent cells.
INTRODUCTION
Recent advances in reprogramming to induced pluripotent stem
cells (IPSCs) have provided access to a wide array of patient-
specific pluripotent lines that have the potential to give rise to
any somatic cell type. A large number of pluripotent lines have
been generated from patients with hematologic diseases,Ceincluding Fanconi anemia (Mu¨ller et al., 2012), sickle cell anemia
(Zou et al., 2011), Diamond Blackfan anemia (Garc¸on et al.,
2013), Shwachman Diamond syndrome (Tulpule et al., 2013),
chronic myelogenous leukemia (Kumano et al., 2012), JAK2V617F
myelo-proliferative disorder (Ye et al., 2009), dyskeratosis con-
genita (Agarwal et al., 2010), Pearson syndrome (Cherry et al.,
2013), and others. These lines have the potential to become
powerful models to gain insight into the molecular basis of dis-
ease and platforms for drug screens (Cherry and Daley, 2013).
To reveal the disease phenotype, IPSCs have to be differentiated
into the target cell type of interest—hematopoietic stem and pro-
genitor cells (HSPCs). Numerous protocols for hematopoietic
differentiation of hPSCs into short-lived progenitors and mature
cells have been established (Chadwick et al., 2003; Kennedy
et al., 2012). However, no system presently exists to generate
large numbers of transplantable cells from human pluripotent
stem cells (hPSCs), thereby precluding disease modeling in vivo
and hampering the scope of experiments and screens that can
be performed.
A major hurdle for generating engraftable HSPCs is the
complex nature of hematopoietic ontogeny. It is now widely
accepted that hematopoietic cells arise during midgestation in
multiple temporal waves from hemogenic endothelial (HE) cells
lining the major arteries (Bertrand et al., 2010; Boisset et al.,
2010). Directed differentiation protocols attempt to recapitulate
ontogeny by calibrated addition of morphogens such as
BMP4, Activin A, and Notch ligands. These protocols can pro-
mote the emergence of HE cells and recapitulate the temporal
waves of hematopoietic progenitors, but they generate few if
any transplantable cells (Choi et al., 2012; Kennedy et al.,
2012). Prior reports of limited engraftment of hPSC-derived cells
in immunodeficient mice have not been widely exploited owing
to the heterogeneity among hPSC lines and variations among
protocols (Ledran et al., 2008; Wang et al., 2005). More impor-
tantly, these protocols generate only small numbers of trans-
plantable cells, and without the possibility of expanding them,ll Stem Cell 13, 459–470, October 3, 2013 ª2013 Elsevier Inc. 459
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Respecification of Engraftable Blood Progenitorsit is difficult to move toward more practical models, such as
in vivo engraftment of disease IPSCs.
One approach that has not been extensively explored in
hematopoietic development is transcription-factor-mediated
specification and expansion of HSPCs. It was recently shown
that a combination of Gata2, Gfi1b, Fos, and Etv6 promotes con-
version of mouse fibroblasts into hematopoietic cells, suggest-
ing that transcription factor reprogramming is a promising
approach (Pereira et al., 2013). However, since fibroblasts are
a distinct cell type, the precise conversion to HSPCs remains a
challenge. We propose that conversions from closely related lin-
eages, which minimize the ‘‘epigenetic distance’’ to a desired
cell type, provide amore favorable context for precise alterations
in cell fate. One possible approach is to promote specification of
HE into transplantable HSPCs, which takes advantage of normal
developmental cues. However, the process of endothelial to
hematopoietic transition remains poorly understood, making it
difficult to design rational interventions. An alternative approach
is to start with committed hematopoietic progenitors and revert
them to a more immature state. Such ‘‘respecification’’ com-
bines directed differentiation with transcription-based reprog-
ramming to establish HSPC fate. A logical hypothesis is that
the key regulatory factors that maintain HSCs can reactivate
stem cell properties, such as self-renewal, in more mature pro-
genitors. Molecular differences between primary human HSCs
and progenitors have been well characterized by gene expres-
sion profiling, thereby enabling a rational approach to introduce
candidate stem cell genes back into progenitors (Doulatov et al.,
2010; Laurenti et al., 2013).
Respecification was likely first demonstrated in mouse embry-
onic stem cells (ESCs) using the homeobox transcription factor
HoxB4. Expression of HoxB4 in lineage-restricted hematopoietic
progenitors isolated from embryoid body (EB) differentiation or
from yolk sac endowed them with extended self-renewal and
long-term multilineage engraftment capacity (Kyba et al.,
2002). HOXB4 has not functioned similarly in human ESCs (Lee
et al., 2008; Wang et al., 2005) or HSCs (Amsellem et al.,
2003), suggesting species-specific differences. These studies,
however, prompted us to search for factors tailored for hPSCs.
Here, we identify HOX- and ETS-family transcription factors
HOXA9 and ERG as inducers of self-renewal and multilineage
potential in hematopoietic progenitors differentiated from
hPSCs. The addition of SOX4 and MYB modulates this network
to enable myeloid and erythroid engraftment, paving the way for
in vivo models of hematological diseases from human IPSCs.
RESULTS
Selection of Candidate Transcription Factors
We hypothesized that introduction of stem cell transcription
factors into hematopoietic progenitors derived from hPSCs
would endow these cells with stem cell properties such as
self-renewal potential. Gene expression of purified mouse
and human HSCs has been extensively analyzed. Since
functionally relevant factors are likely conserved, we used
two independent mouse (Chambers et al., 2007; Ivanova
et al., 2002) and two human (Doulatov et al., 2010; Novershtern
et al., 2011) data sets to select transcriptional regulators
more highly expressed in HSCs compared with progenitors or460 Cell Stem Cell 13, 459–470, October 3, 2013 ª2013 Elsevier Inc.mature cells. Factors enriched in either of the two species-
specific data sets were intersected to identify conserved regu-
lators. These were then compared with gene sets differentially
regulated during ontogeny to select factors upregulated in
definitive HSCs (McKinney-Freeman et al., 2012). From this list
of 32 HSC-specific transcription factors, 9 are significantly
underexpressed in CD34+CD45+ EB progenitors compared
with CD34+CD38 cord blood (CB) HSCs (Wang et al., 2005).
These are ERG, KLF4, SOX4, MYB, RORA, HLF, HOXA5,
HOXA9, and HOXA10. These open reading frames were
cloned into a pSMAL-GFP lentiviral vector. Lentiviruses were
produced as a minilibrary of nine factors (9F), plus luciferase
(LUC), which serves as an internal control (Figure S1A available
online).
An In Vitro Screen for Self-Renewal Capacity
To generate hematopoietic progenitors, hPSCs were differenti-
ated as EBs in the presence of BMP4 and cytokines, as previ-
ously described (Chadwick et al., 2003). An ESC line, CHB6,
and an IPSC line, MSC-IPS1, were selected based on their
robust hemogenic potential (Figure S1B). In these conditions,
CD34+CD45+ progenitors appear at day 10 and expand until
day 14 (Figure 1A). Since EBs in our protocol are cultured with
serum, the day 14 progenitors likely represent a mixture of prim-
itive and definitive cell types (Figure S1C). Progenitors isolated
by flow sorting at day 14 possess robust myeloid colony-forming
activity, but produce few erythroid or mixed colonies (Figure 1B).
When cultured in serum-free media with cytokines, they rapidly
differentiate and lose this potential, and after 7 days in culture
no colonies are ever observed, indicating a complete lack of pro-
liferative and self-renewing potential (Figure 1B). We reasoned
that if a combination of factors allowed progenitors to proliferate
and undergo self-renewal divisions—a basic property of HSCs—
these would appear as rare colonies after extended culture. To
test the candidate transcription factors in this simple screen,
CD34+CD45+ progenitors were infected with the 9F library,
cultured for 7 days, and plated in colony assays. Both CHB6
and MSC-IPS1 progenitors infected with 9F, but not LUC alone,
consistently gave rise to colonies in independent experiments
(Figure 1C). Single colonies were isolated and analyzed for the
presence of integrated viral transgenes (Figure 1D). The fre-
quency of LUC integrations controlled for infection efficiency,
with more frequent integrations being under positive selection.
Each colony harbored four to eight integrations, with HLF,
ERG, HOXA9, and RORA present in almost every colony. In an
independent experiment with a lower transduction efficiency,
HOXA9 and RORA were also under selection (Figure S1D). The
colony-forming capacity could be sustained for at least 3 weeks
in culture (Figure 1E). To further investigate this renewal poten-
tial, we carried out serial replating. Some, but not all, 9F-infected
replicates had robust replating potential (Figure 1F). Almost all
colonies from the replicates with high replating potential had
HLF, ERG, HOXA9, and RORA integrations. By contrast, col-
onies from the poorly replating replicates harbored fewer inte-
grations (Figure 1G) suggesting that higher-order combinations
were important.
Retrospective analysis has identified HLF, ERG, HOXA9,
and RORA as candidate factors that endow embryonic hema-
topoietic progenitors with self-renewal capacity. To test them
Figure 1. In Vitro Screen for Progenitor Respecification
(A) The scheme for EB differentiation of hPSCs into hematopoietic progenitors. EBs cultured in serum, BMP4, and cytokines are dissociated after 14 days.
CD34+CD45+ progenitors are isolated by flow sorting and transduced with a 9F lentiviral library.
(B) Colony-forming capacity of CD34+CD45+ EB progenitors from MSC-IPS1 and CHB6-ESC after sorting (day 0) is lost after 7 days of culture in serum-free
media.
(C) Representative plates of CHB6 EB progenitors transduced with the 9F library showing emergence of de novo hematopoietic colonies after 7 days of culture.
(D) Retrospective analysis of transgene insertions in individual colonies isolated from replicate #1 in (C). LUC is an internal control for transduction efficiency.
Columns ‘‘+’’ and ‘‘–’’ are positive and negative controls for PCR.
(E) Colony counts and types observed after 7 or 14 days of culture of luciferase (Luc) or 9F-transduced progenitors.
(F) Serial replating potential of 9F replicates.
(G) Transgene insertions for a nonreplating sample (replicate #2 in C) show that most colonies do not contain higher-order combinations of the common
integrations.
Data are shown as mean ± SEM of three independent samples. See also Figure S1.
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nations of the four factors and assayed each by plating colonies
at day 7 of culture. Rare colonies appeared in single ERG-
or HOXA9-transduced samples, but both ERG and HOXA9
(abbreviated ‘‘EA’’) were required for robust colony-forming ac-
tivity in both CHB6 and MSC-IPS1 progenitors (Figures 2A–2C
and Figures S2A and S2B). The addition of RORA (abbreviated
‘‘EAR’’) enhanced colony formation, while addition of HLF did
not alter the number of colonies for any combination of factors
(Figure 2B). EA colonies were larger in size, whereas EAR
specified more colonies. Consistent with this, EA cultures
proliferated more rapidly than EAR, which contained more pro-
genitors with slower cell cycle kinetics (Figures 2D and 2E). No
colonies were observed in any single-infected samples after
14 days of culture. ERG or HOXA9 single-transduced samples
also never gave rise to secondary colonies, implying that multi-
ple factors are required for respecification. By contrast, most
of the EAR-transduced replicates could be serially replatedCe(Figures 2B, S2A, and S2B). Based on these data we included
RORA in subsequent experiments.
Our data suggest that activation of self-renewal in hPSC-
derived progenitors requires at least two transcription fac-
tors—HOXA9 and ERG. Notably, EA also promoted renewal of
CB CD34+ progenitors in vitro, and the possibility of respecifying
adult progenitors to HSPCs warrants further exploration (Fig-
ure S2C). HOXA9 is the key homeotic gene that defines HSPC
identity (Di-Poı¨ et al., 2010; Lawrence et al., 2005). ERG is a
component of HSC renewal during embryogenesis and stress
hematopoiesis (Loughran et al., 2008). ERG is also a transcrip-
tional target of HOXA9, suggesting a basis for their functional
cooperation in our assay (Huang et al., 2012).
HOXA9, ERG, and RORA Establish a Hematopoietic
Hierarchy
Individual lineages in the hematopoietic hierarchy can be accu-
rately distinguished by a combination of cell surface antigens.ll Stem Cell 13, 459–470, October 3, 2013 ª2013 Elsevier Inc. 461
Figure 2. Self-Renewal Is Driven by HOXA9,
ERG, and RORA
(A–C) Prospective analysis of HOXA9 (A), ERG (E),
HLF (H), and RORA (R) combinations in CHB-ESC
(A and B) and MSC-IPS1 (C) (see also Figure S2A)
progenitors using the in vitro colony assay. Inde-
pendent pluripotent lines are shown to demon-
strate reproducibility of the factor combinations.
Representative plates for combinations of HOXA9,
ERG, and RORA are shown in (A) and (C), and the
full quantitation of primary and secondary colony-
forming efficiency is shown in (B). Numbers above
the plates indicate an average number of colonies
per 104 cells plated. Numbers below secondary
bars indicate the fraction of replicates that gave
rise to secondary colonies.
(D) Proliferation of ERG, HOXA9, and RORA (EAR)-
transduced progenitors compared with ERG and
HOXA9 without RORA (EA) and LUC control.
(E) Cell cycle analysis of EA- and EAR-induced
CD34+ cells and the more mature lineage-positive
(Lin+; defined as CD14+, CD15+, or CD11b+) cells
with or without RORA after 14 days of culture.
All data are shown as mean ± SEM of at least
three independent replicates. See also Figure S2.
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progenitor subsets that resemble those found in CB or adult
marrow. Cultured EB CD34+CD45+ progenitors completely
differentiate into CD34 cells after 7 days of culture, which is
consistent with loss of clonogenic capacity (Figure 3A). By
contrast, a CD34+ population was maintained in EAR cultures,
expanding between 7 to 14 days, and persisting after that
(Figure 3A). CD34+ cells were also found in dissociated primary
colonies, accounting for serial replating. CD34 expression
segregated with the lineage-negative population that did not
express myeloid markers CD14, CD15, or CD11b. Human
HSCs are found exclusively in the CD34+CD38 compartment,
and the loss of stem cell potential is correlated with the gradual
acquisition of CD38 and loss of CD34 expression (Mazurier et al.,
2003). The starting EBs lack a clearly defined CD34+CD38 pop-
ulation (Figure 3B). By contrast, EAR established a pattern of
CD34 and CD38 closely resembling that of lineage-depleted
CB (Figure 3B). CD90+CD49f+ cells could be further identified
within the CD34+CD38 EAR compartment, which is highly
enriched for HSCs in CB (Figure 3B) (Notta et al., 2011). Thus,
the three factors establish a rudimentary HSPC hierarchy, even
in the presence of constitutive transgene expression.
HOXA9, ERG, and RORA Reactivate Expression of HSC
Genes
To clarify the molecular basis for self-renewal of respecified
progenitors, we performed microarray profiling of CD34+
CD38 cells isolated by flow sorting from EBs, EAR cultures,
and primary CD34+CD38 HSCs and CD34+CD38+ progenitors
from CB and fetal liver (FL). Unsupervised clustering showed
that these populations segregated to distinct branches, indi-
cating broad differences in gene expression (Figure 4A). To
define the molecular program initiated by the factors, we identi-
fied genes induced or repressed greater than 2-fold by EAR in
EB progenitors (t test, FDR < 0.05; Table S1 available online).462 Cell Stem Cell 13, 459–470, October 3, 2013 ª2013 Elsevier Inc.The majority of these 2,070 genes were concordantly expressed
in HSCs (Figure 4B), including genes on in HSCs activated by
EAR (group A) and genes off in HSCs repressed by EAR (group
C). The transcription factors induced by EAR include RUNX1,
HLF, the AP-1 family (FOS, JUN, MAFF), and GFI1B, all critical
elements of a normal HSC program (Figure 4B). To analyze this
using a different metric, we employed refined signatures for
the human HSPC hierarchy (Laurenti et al., 2013). Six signatures
capture the major patterns of early transcription: HSC, MLP
(early lymphoid), HSC_MLP (shared stem and lymphoid),
GMP (myeloid), CMP_MEP (erythroid), and Progenitor (shared
between all progenitors). HSC and HSC_MLP signatures were
significantly enriched in EAR compared to EBs (Figure 4C,
bottom row). By contrast, progenitor signatures were enriched
in EBs (Figure 4C, top row). These data show that while factor-
transduced progenitors retain similarity to EBs, EAR initiates a
gene expression program that is shared with normal HSCs.
To further analyze transcriptional changes induced by the
three factors, we performed gene-set enrichment analysis for
annotated gene sets in the MSigDB database. HSC gene sets
andHOXA9 targets were enriched in EAR, while cell cycle, serum
response, and oncogene-induced gene sets were enriched in
EBs (Figure S3A). To test if the factors turn on some HSC-spe-
cific genes and repress progenitor-specific genes, we compiled
a list of genes differentially expressed between CB/FL HSCs
and progenitors (t test, FDR < 0.05; Table S2). Genes on in
HSCs were largely off in EBs, indicating a loss of stem cell
gene expression. EAR activated some of these genes, although
the trend did not reach significance (Figure S3B). This was
mirrored by HSC-specific transcription factors, most of which
were underexpressed in EB progenitors (Figures 4D and 4E).
We discerned two patterns of expression in response to EAR:
factors reactivated by EAR to levels similar in HSCs, including
HLF, NFIB, HOPX, HMGA2, and RBPMS (Figure 4D), and tran-
scription factors not affected by EAR, such as GATA3,
Figure 3. Factor-Based Establishment of Hematopoietic Hierarchy
(A) Progressive loss of CD34+ progenitors in control serum-free cultures (LUC) while EAR maintains and expands CD34+ cells (right panels).
(B) Detailed analysis of the phenotypic HSC compartment in EBs, EAR cultures (from dissociated colonies), and primary CB. Lineage-positive cells are gated out
(using a combination of CD14/CD15/CD11b for EBs andEAR). CD34 andCD38 delineates CD34+CD38HSCs andCD34+CD38+ progenitors (top). CD34+CD38
fraction is further marked by CD90 and CD49f (bottom) with double positive cells being the most primitive in CB.
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tors MEIS1 and PBX1 also belonged to this group. Genes off in
HSCs and on in progenitors, including myeloid and erythroid
transcription factors, such as GATA1, KLF1, LEF1, CEBPA,
andMITF, were highly expressed in EBs and significantly down-
regulated by EAR (Figures 4F and S3B). These data suggest that
EB progenitors lack the functional properties of HSCs not only
because they fail to upregulate HSC-specific genes, but also
because they express negative regulators of stem cell function
that define differentiated cells (see Table S3 for EB versus HSC
gene list). While respecified progenitors remain different from
HSCs (see Table S4 for EAR versus HSC gene list), EAR upregu-
lated a subset of HSC-specific genes and repressed progenitor
genes, which likely accounts for their capacity to induce self-
renewal in progenitors.
In Vivo Engraftment Requires SOX4 and MYB
We next tested if transcription-factor-respecified progenitors
can successfully engraft in irradiated mice. After 2 weeks of
primary culture, 1 3 106 EAR cells were transplanted into
NOD/SCID-IL2Rgnull (NSG) mice. We found no detectable
human engraftment 4 weeks after transplant using two indepen-
dent CD45 antibodies to accurately detect human chimerism
(n = 10). This indicated that either EAR was insufficient for even
short-term engraftment or that changes induced during culture
impaired their capacity for homing and retention in the bone
marrow. At the same time, we also transplanted 9F library-
transduced progenitors. One mouse that had received a trans-
plant into the right femur had a 0.2% human engraftment
after 4 weeks (Figure 5A). The integration pattern in CD45+ cells
isolated by flow sorting showed the presence of SOX4 and
MYB transgenes in addition to EAR (Figure 5A). This finding
suggested that different transgenes were selected during
in vivo reconstitution and led us to believe that the addition of
SOX4 and MYB to our cocktail of transcription factors would
enable engraftment of EB-derived progenitors.CeTranscription Factors Respecify Myeloid-Restricted
Precursors into Multilineage Progenitors
To investigate the functional outcome of combining SOX4 and
MYB with HOXA9, ERG, and RORA (EARSM), we infected
CD34+CD45+ progenitors as before and carried out colony
assays after 14 days of culture. While EAR gave rise to only
myeloid colonies, the addition of SOX4 and MYB prompted the
appearance of a large number of blast erythroid (BFU-E) and
mixed myelo-erythroid (CFU-GEMM) colonies (Figure 5B). The
appearance of GEMM colonies was notable since these are
typically not detected, or very rare, among CD34+CD45+ EB
progenitors. Mixed colonies contained both CD11b+ myeloid
and CD235a+ erythroid cells. Myelo-erythroid cells were only
found in the GFP fraction, whereas GFP+ cells were CD11b+
or CD34+ (Figure 5C), suggesting that erythroid potential was
only realized upon transgene silencing.
To explore this possibility, we switched to an inducible lentivi-
ral system in which rtTA is expressed from the same vector as
the transgene (Meerbrey et al., 2011). Progenitors were infected
with five inducible lentiviruses and cultured in doxycycline (Dox)
before colonies were plated with or without Dox. As predicted,
GEMM colonies formed only upon Dox withdrawal (Figure 5D).
Colonies plated with Dox contained a mixture of CD11b+ cells
and CD34+ self-renewing progenitors; rare erythroid cells were
always derived from transgene silencing (Figure 5E). Upon Dox
withdrawal, CD34+ progenitors differentiated completely into
CD235a+CD71+ erythroid or CD11b+ cells (Figure 5E). Rapid
cessation of self-renewal upon Dox withdrawal is explained by
the lack of endogenous HOXA9 and ERG transcription, making
the system sensitive to induced transgene expression (Fig-
ure S4). This presents an attractive system with a high degree
of control over self-renewal versus differentiation to model
normal and disease hematopoiesis.
Two hypotheses can be put forward to account for the
appearance of mixed colonies after factor transduction. One
possibility is expansion of the rare GEMM progenitors presentll Stem Cell 13, 459–470, October 3, 2013 ª2013 Elsevier Inc. 463
Figure 4. Gene Expression Analysis of Respecified Progenitors
CD34+CD38 cells respecified with EAR (fractions A and F) were compared to
their respective starting CHB6-ESC and MSC-IPSC EBs (fractions E and K),
primary CB and FL HSCs (fractions C and G), and CD34+CD38+ progenitors
(fractions D and H) by Affymetrix microarray profiling. Each sample was iso-
lated by flow sorting with two or three biological replicates (#1–3).
(A) Unsupervised global clustering of all probes. Bootstrap values indicate
confidence levels.
(B) Supervised clustering of 2,070 genes differentially expressed between
CD34+CD38 EBs and EAR progenitors respecified from them (>2-fold; t test,
FDR < 0.05). Clusters of differential genes are marked A–D. Transcription
factors significantly upregulated by EAR (from clusters A and B) are boxed on
the right. See Table S1 for a full list of genes.
(C) Gene set enrichment of human HSC and progenitor signatures in EBs
compared with EAR progenitors. ES = enrichment score; NES = normalized
enrichment score; all comparisons were significant with FDR < 104,
except MLP.
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464 Cell Stem Cell 13, 459–470, October 3, 2013 ª2013 Elsevier Inc.in the day 14 EBs. Due to heterogeneity among hPSC lines, rare
GEMM colonies were in fact detected in MSC-IPS1, but not
CHB6 EB progenitors (Figure 5F). In stark contrast, the emer-
gence of GEMM colonies after EARSM transduction was effi-
cient (up to 25% of all colonies) and highly reproducible with
both CHB6 andMSC-IPS1 lines (Figure 5F). We tested the effect
of culture on immobilized Delta1, which has been shown to sup-
port the expansion of HSPCs by providing a low level Notch
signal (Delaney et al., 2005). Delta1-cultured progenitors trended
toward higher numbers of GEMM colonies, but the trend did not
reach significance. To examine this further, we screened a panel
of IPSC lines and identified two lines, BJ-IPS1 and CD45-IPS1,
derived from normal foreskin fibroblasts and CD45+ peripheral
blood cells, respectively, that did not give rise to BFU-E or
GEMMcolonies (Figure 5F, ‘‘Other IPSCs’’). Both lines reproduc-
ibly gave rise to erythroid andmixed colonies after induction with
EARSM (Figure 5F). These data argue against the possibility that
the factors simply expand progenitors present in the starting EBs
and instead suggest that they actively respecify myeloid-
restricted precursors to a myelo-erythroid fate.
Lymphoid potential is critical evidence for respecification,
since EB progenitors do not generate B or T cells (Martin et al.,
2008). To test lymphoid potential, we seeded EAR-transduced
cells on OP9-DL1 stroma that promotes T cell differentiation.
CB CD34+ cells progress through well-defined stages of differ-
entiation, starting with the acquisition of early lymphoid markers
CD7 and CD5 and culminating with CD4+CD8+ lymphocytes.
We noted that EAR cultures from which Dox was removed failed
to proliferate; however, continued exposure to Dox reduced
maturation past the CD7+ stage. Cultures in which Dox was
added for the first 2 weeks only showed improved maturation,
with more than 4% of lymphocytes reaching the CD4+CD8+
stage after 5 weeks (Figure 5G). Similar frequencies of CD1a+
and CD3+ cells were observed (Figure S5). By comparison,
>13% of CB CD34+ cells were CD4+CD8+ with robust coex-
pression of CD1a and CD3 (Figures 5G and S5). These data
show that factor-induced progenitors harbor lymphoid potential
indicative of respecification to a definitive cell type. However,
their lymphoid potential is considerably less than that for adult
progenitors, and further optimization of transcription factor
combinations is needed.
Respecified Progenitors Mediate Short-Term
Myeloid and Erythroid Engraftment
The establishment of a robust and reproducible transplantation
model from hPSCs is an important goal. To test the engraftment
potential of respecified progenitors, we used the inducible
transgene system to expand EB-derived progenitors for
14 days with Dox, and transplanted 0.8–1.2 million cells(D–F) Expression levels of top differentially expressed transcription factors
(ranked by fold change) between CB and FL HSCs and progenitors (>2-fold;
t test, FDR < 0.05; see Table S2 for a full gene list). Expression values are
median transformed relative to all probes. (D) HSC transcription factors
significantly upregulated by EAR. (E) HSC transcription factors not induced
EAR. (F) Progenitor transcription factors significantly repressed by EAR.
Data are shown as mean ± SEM of six total biological replicates for HSCs, or
five replicates for progenitors, EBs, and EAR. See also Figure S3, Table S3,
and Table S4.
Figure 5. Respecification of Myeloid-Restricted Precursors into
Multilineage Progenitors
(A) Detailed analysis of human engraftment in a mouse transplanted with 9F
cells after 14 days of culture. Two independent CD45 antibodies (CD45-1 and
CD45-2) were used to label human cells. (Right) Transgene insertions in
CD45+ cells (column H) isolated from this mouse by flow sorting show SOX4
and MYB integrations.
(B) Colony-forming efficiency of EB progenitors transduced with EA, EAR, and
EARSM (+SM) after 14 days of culture.
(C) Flow analysis of dissociated EARSM colonies using CD235a (erythroid) and
CD11b (myeloid) lineage markers. At least ten GEMM colonies were pooled,
and plots are gated on GFP+ or GFP populations.
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Ce(expanded from <5,000 EB CD34+CD45+ cells) into the femurs
of adult NSG mice. Human engraftment was evaluated after
4 or 8 weeks using two human CD45 antibodies, erythroid
(CD235a), myeloid (CD33), and lymphoid (CD19, CD5) lineage
markers.
Mice transplanted with MSC-IPS1 EARSM progenitors were
engrafted in the injected femur after 4 weeks, and at lower levels,
in the rest of bone marrow (Figure 6A and Figure S6A). We
observed only minimal engraftment in mice when Dox was
removed (Figure S6B). When Dox was administered, almost all
injected mice were engrafted, with an average engraftment
across several independent experiments and culture conditions
of 2.1% (9 of 12 mice engrafted >0.1%). Similar engraftment
levels were observed with CHB6-ESC progenitors (average
0.63%, three of four mice engrafted >0.1%) (Figure 6B). In
most recipients, both myeloid and erythroid cells were present;
however, in some mice only myeloid or only erythroid engraft-
ment was found (Figure 6C). By contrast with CB-transplanted
mice, we did not detect CD19+ B cells. To test the reproducibility
of this system using independent IPSC lines, we transplanted
EARSM-transduced progenitors derived from BJ-IPS and
CD45-IPS lines. We observed a similar myelo-erythroid pattern
of engraftment in these mice (Figure 6D). In total, 16 of 21 mice
transplanted from four hPSC lines were engrafted, with an
average engraftment of 2.7% (Figure 6E).
The presence of erythroid engraftment was notable since
immunodeficient mice do not robustly support human erythro-
poiesis (Hu et al., 2011). We observed that several mice with
symptoms of radiation sickness—low weight, enlarged spleens,
and peripheral lymphocytopenia—had high levels of erythroid-
only engraftment, suggesting that intense myeloablation pro-
motes erythropoiesis in this model (Figure 6C). Erythroid
development in vivo was not inhibited by exposure to Dox
possibly due to lower effective levels in tissues. Engraftment
levels declined during extended transplantation. Low-level
myeloid engraftment persisted 10–12 weeks posttransplant;
however, erythroid cells were not detectable beyond 6 weeks
(Figure S6C). These findings demonstrate that progenitors
respecified from multiple hPSC lines mediate reproducible
short-term engraftment.(D) Colonies plated with or without Dox in the inducible transgene system.
Erythroid and mixed colonies appear only upon Dox withdrawal. (Right)
Representative images of CFU-GEMM, BFU-E, and CFU-GM colonies on
plates without Dox.
(E) Self-renewing CD34+ progenitors differentiate into myeloid and erythroid
cells upon Dox removal. Flow analysis of dissociated EARSM colonies using
the CD34 progenitor marker (left panels) and lineage markers CD11b and
CD235a (right panel) is shown.
(F) Respecification of EB myeloid precursors into mixed lineage CFU-GEMM
progenitors fromMSC-IPS1 (left), CHB6-ESC (middle), and two other myeloid-
restricted IPSC lines (right). EB progenitors were infected with EARSM and
cultured with or without immobilized Delta1 ligand. Each groupwas platedwith
or without Dox.
(G) T cell potential of respecified cells in an OP9-DL1 stromal coculture. EAR-
induced cells were cultured on OP9-DL1 without Dox (EAR  Dox), with Dox
(EAR + Dox), or with Dox for the first 2 weeks followed by Dox removal (EAR
switch). Development of CD4+CD8+ T cells was assessed following 35 days of
culture, compared with CB CD34+ cells. Plots are gated on CD45+ cells.
Data in (B) and (F) are shown as mean ± SEM of at three independent repli-
cates. See also Figures S4 and S5.
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Figure 6. Short-Term Engraftment of Re-
specified Progenitors
EB progenitors derived from MSC-IPS (A) or
CHB6-ESCs (B) were respecified with inducible
EARSM for 7–16 days, and 0.8 to 1.2 3 106 cells
were transplanted into the right femur of adult NSG
mice. As a control, 1 3 106 CB mononuclear cells
were transplanted. All mice received Dox in the
drinking water. Human engraftment was analyzed
4–5 weeks posttransplantation using two human
CD45 (myeloid, lymphoid) and CD235a (erythroid)
antibodies. Only engraftment the injected femur
is shown.
(A) Representative myelo-erythroid engraftment
in EARSM- (left) and CB- (middle) transplanted
mice. Cells positive for CD45 are subgated
on CD19 and CD33 (bottom row). At right is a
representative mouse engrafted only with human
erythroid cells. CD235a+ cells are subgated on
CD71 and mouse Ter119.
(B) Representative engraftment in CHB6-ESC
mice.
(C) Myeloid and erythroid lineage distribution in
engrafted (>0.1% of human chimerism) MSC-IPS
and CHB6-ESC mice. The height of the bar in-
dicates total engraftment level calculated as %
CD235a plus %CD45+.
(D) Representative engraftment in mice trans-
planted with independently-derived IPSC lines,
BJ-IPS, and CD45-IPS.
(E) Summary of engraftment level in all trans-
planted mice with four different hPSC lines.
See also Figures S6 and S7.
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and MYB on engraftment, we carried out expression profiling
of CD34+CD38 cells induced with the five factors. These
samples clustered closely to EAR, indicating an overall similar-
ity between all respecified progenitors (Figure S7A). Gene
ontology categories for hematopoietic development and im-
mune function were enriched among genes differentially regu-
lated by EARSM relative to EAR (Figure S7B). EAR was asso-
ciated with aberrant induction of a number of genes, such as
heat-shock proteins (HSPA6) and Fcg receptors (FCGR2A,
FCGR2B, and FCGR2C) (Figure S7C). Repression of these tran-
scripts by SOX4 and MYB may restore engraftment capacity
of in vitro-specified cells.
Globin Switching during In Vivo Human Erythropoiesis
A pervasive feature of erythroid differentiation from hPSCs is the
retention of embryonic and fetal patterns of globin expression
(Chang et al., 2006; Dias et al., 2011). This property has been
reported using independent protocols, suggesting that erythroid
precursors fail to receive cues that promote proper develop-
mental maturation reflected by globin gene switching (Anstee
et al., 2012). Consistent with reported findings, BFU-Es isolated
fromCD34+CD45+ EBs expressed embryonic ε globin and fetal g
globin, but little or no adult b globin (Figure 7A). Respecification
with EARSM did not alter this pattern of globin expression in vitro
(Figure 7A). An important question that we sought to address is
whether the adult bone marrowmicroenvironment could provide
the cues to alter globin preference. To this end, we analyzed466 Cell Stem Cell 13, 459–470, October 3, 2013 ª2013 Elsevier Inc.erythroid engraftment in EARSM-transplanted mice. Mouse
erythrocytes were gated out with anti-mouse Ter119, showing
that the majority of human erythrocytes were CD235a+CD71+
(Figure 7B). The marrow of cytopenic mice contained more
Ter119+ cells reflective of stress erythropoiesis, accompanied
by progressive maturation of human erythrocytes (Figure 7B).
The majority of sorted human CD235a+CD71+ cells were at the
late erythroblast-normoblast stage of differentiation by
morphology (Figure 7C) and marked by high levels of Band3
and low levels of CD49d (Figure 7D). Human erythrocytes do
not readily enucleate in vivo; however, we detected some
enucleated cells both by morphology and nuclear dye uptake
(Figures 7C and 7D). Thus, hPSC-derived progenitors undergo
erythroid maturation in vivo.
We next examined the pattern of hemoglobin expression in
CD235a+CD71+ erythroblasts isolated from engrafted mice.
Remarkably, ε globin was suppressed (4.0% of total globin,
range 0.9%–7.1%), and b globin (12.6% of total globin, range
3.6%–28.1%) was induced, compared to cultured erythroblasts
(Figure 7E). As expected, mice engrafted with CB expressed
a mixture of g and b globins. These findings were supported
by analysis in single sorted CD235a+CD71+ cells. Single CB cells
isolated from colonies or engrafted mice almost uniformly coex-
pressed g and b globins (Figure 7F). Remarkably, 41.9% of
EARSM-engrafted cells coexpressed g and b globin, and a sig-
nificant proportion (12.9%) expressed only b globin (Figure 7F).
By comparison, adult globin-expressing cells were never de-
tected in vitro (Figure 7F). The total levels of globin transcripts,
Figure 7. In Vivo Globin Switching in Embryonic Erythrocytes
(A) Quantitative PCR for the expression of adult HBB (b), fetal HBG (g), and
embryonic HBE (ε) hemoglobin genes in BFU-E colonies derived from EBs,
EARSM (5F), and CB. Expression of each gene was calculated using absolute
quantification and displayed as percent of total globin transcript.
(B) Analysis of human erythroid graft in two normopenic (Mouse 1 and 2) and
two cytopenic EARSM mice using human CD71 and CD235a. Plots are
subgated on Ter119 mouse cells, and the percent of mouse erythrocytes is
indicated.
(C) Giemsa staining of Ter119CD71+CD235+ human erythrocytes. Repre-
sentative single cells and clusters are shown.
(D) Erythroid maturation in vivo and in vitro determined by expression of
Band3 and CD49d (integrin a4). Progressive maturation is marked by high
levels of Band3 and loss of CD49d (gated population). Only CD235a+ cells
are shown. At right, the proportion of enucleated erythrocytes in vivo using
cell-permeable nuclear dye SYTO60 (gated SYTO60 population) is shown.
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Ceand the degree of erythroid maturation as evidenced by
Band3 and CD49d, were similar between cells isolated in vitro
or in vivo (Figure 7D). These findings demonstrate that human
IPSC-derived erythroid precursors respecified with transcription
factors undergo hemoglobin switching in vivo, giving rise to
definitive erythrocytes.DISCUSSION
Generation of engraftable HSPCs from human pluripotent cells
is a major goal in regenerative medicine. Here we report a sig-
nificant advance toward this goal using a transcription-factor-
mediated approach. In our system hPSCs are differentiated
to hematopoietic progenitors and then transduced with a combi-
nation of HSC transcription factors that aim to respecify these
progenitors to a stem cell fate. Using an in vitro screen to identify
relevant combinations of factors, we demonstrate that HOXA9,
ERG, and RORA convert myeloid-restricted precursors into
self-renewing multilineage HSPCs with erythroid and lymphoid
potential. These factors are sufficient to expand progenitors
while maintaining a hierarchy with CD34+CD38 ‘‘stem cells.’’
HOXA9 and ERG can be further modified by SOX4 and MYB to
enable short-term myelo-erythroid engraftment. These findings
establish a transcription-factor-based system for engraftment
from hPSCs that will serve as a platform for further improve-
ments in transplantation potential.
The advent of IPSC technology has enabled the generation of
pluripotent lines from patients with hematologic diseases. The
hope has been that these lines can serve as models to gain
insight into the molecular basis of these diseases and as plat-
forms for drug screens (Cherry and Daley, 2013). However, the
inability to generate large numbers of engraftable cells has pre-
cluded disease modeling in vivo, thereby limiting the scope of
experiments and drug screens that can be performed. Our
system described here may be suitable for modeling anemias
and other red blood cell disorders due to its ability to generate
large numbers of erythroid precursors in vitro, robust erythroid
engraftment that can be enhanced by intensive myeloablation,
and a high degree of hemoglobin maturation in vivo. Due to
the near-unlimited capacity to produce erythroid cells, this
transcription factor approach may also be suitable for transfu-
sion-related applications (Migliaccio et al., 2012).
Erythroid precursors differentiated from hPSCs express
embryonic and fetal, but not adult, hemoglobin (Chang et al.,
2006). Induction of a switch to adult globin, critical for modeling
thalassemias and sickle cell anemia caused by mutations in
the HbB locus, has been the subject of intense investigation.(E) Hemoglobin expression in Ter119CD71+CD235+ human erythroblasts
isolated from the marrow of multiple mice transplanted with CB or EARSM
progenitors, in comparison with BFU-Es from EBs, 5F, and CB.
(F) Hemoglobin expression in single Ter119CD71+CD235+ erythroblasts
isolated from transplanted mice (IN VIVO) or from cultured BFU-Es (IN VITRO).
The cutoff for coexpression was set at 10% (i.e., a cell with 90%/10% ratio
of b/g transcript is classified as bg, while 95%/5% is classified as b-only).
Single-cell expression was validated by comparing against wells sorted with
50 cells.
Data in (A) and (E) are shown as the mean ± SEM of at least two samples. Data
in (F) represents >80 sorted single cells.
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Respecification of Engraftable Blood ProgenitorsSilencing of embryonic and fetal globins is mediated by BCL11A,
in tandem with KLF1, MYB, and others (Sankaran and Orkin,
2013; Sankaran et al., 2009). One possibility is that the ex-
pression or activity of these factors is not induced during hPSC
differentiation in vitro resulting in the persistence of embryonic
and fetal globins. The finding that erythrocytes in transplanted
mice silence embryonic and induce adult globins supports the
long-standing hypothesis that the bone marrow microenviron-
ment can promote globin switching. This raises the possibility
that globin switching is initiated by specific signaling pathways
that activate BCL11A and other regulators following the migra-
tion of HSCs from FL to bone marrow after birth. The nature
of these signals remains completely unknown. Since globin
switching is regulated in a species-specific manner, transplan-
tation of hPSC progenitors can serve as a model to interrogate
the nature of the signaling interactions that drive globin switching
(Sankaran et al., 2009).
Transcription factors that control stem cell state act as part of
complex gene regulatory networks, and while these networks
have been extensively modeled, functional studies have largely
focused on the role of individual factors in controlling HSC fate
(Orkin and Zon, 2008; Wilson et al., 2010). The respecification
approach presents an opportunity to identify functional networks
of cooperating factors. HOXA9 and ERG have been known to
be required for HSC specification and expansion (Lawrence
et al., 2005; Loughran et al., 2008). Both factors are also known
oncogenes, and it is now well-established that normal self-
renewal programs, if constitutively activated or dysregulated,
can promote aberrant expansion of leukemic cells (Eppert
et al., 2011). Our findings demonstrate that HOXA9, ERG,
RORA, SOX4, and MYB are part of the same functional gene
regulatory network. HOXA9 occupies ERG, SOX4, and MYB
promoters, linking them on a molecular level (Huang et al.,
2012). We propose that this network may have an important
role in adult HSCs and leukemia-initiating cells. Our approach
may provide deeper insights into the principles underlying
the organization of HSC networks.
Current strategies for deriving HSPCs from heterologous cell
types are based on directed differentiation from hPSCs or re-
programming of somatic cells (Pereira et al., 2013). We propose
a hybrid strategy aiming to respecify HSCs from closely related
progenitors by activating stem cell gene regulatory networks.
However, respecification with our current factors has not
achieved the major goal of generating a cell with long-term and
multilineage repopulation potential. HSC state is controlled by
a large number of transcription factors and epigenetic modifiers
(Doulatov et al., 2012; Orkin and Zon, 2008). Powerful screening
strategies are thus needed to identify rare combinations of
cooperating factors. Our approach is based on detecting clono-
genic progenitors arising as a result of self-renewal divisions
in culture. However, these cell states may be incompatible with
the in vivo requirements for HSC function. The alternative is to
respecify directly in vivo to take advantage of the cues that
normally support HSC self-renewal. However, only very rare
combinations can likely be detected in this setting. The strategy
we describe here provides a logical platform for pursuing
both in vitro and in vivo screens aiming to reveal improved
sets of factors that extend stem cell properties of respecified
progenitors.468 Cell Stem Cell 13, 459–470, October 3, 2013 ª2013 Elsevier Inc.EXPERIMENTAL PROCEDURES
Details on colony assays, flow cytometry, microarray profiling, mouse trans-
plantation, assessment of human cell engraftment, and quantitative and
single-cell PCR are described in the Supplemental Experimental Procedures
available online.
hPSC Culture
All experiments were performed with CHB6 ESC (NIH #0006) and MSC-IPS1
(Park et al., 2008). Human ESCs and IPSCs were maintained on mouse
embryonic fibroblasts (GlobalStem) feeders in DMEM/F12 + 20% KnockOut-
Serum Replacement (Invitrogen), 1 mM L-glutamine, 1 mM NEAA, 0.1 mM
b-mercaptoethanol, and 10 ng/ml bFGF. Media was changed daily, and cells
were passaged 1:4 onto fresh feeders every 7 days using standard clump
passaging with collagenase IV.
EB Differentiation
EB differentiation was performed as previously described (Chadwick et al.,
2003). Briefly, hPSC colonies were scraped into nonadherent rotating 10 cm
plates. EB media was KO-DMEM + 20% FBS (Stem Cell Technologies),
1 mM L-glutamine, 1 mM NEAA, penicillin/streptomycin, 0.1 mM b-mercap-
toethanol, 200 mg/ml h-transferrin, and 50 mg/ml ascorbic acid. After 24 hr,
media was changed by allowing EBs to settle by gravity and replacing with
EB media supplemented with growth factors as follows: 50 ng/ml BMP4
(R&D Systems), 300 ng/ml SCF, 300 ng/ml FLT3, 50 ng/ml G-CSF, 20 ng/ml
IL-6, 10 ng/ml IL-3 (all Peprotech). Media was changed on day 5 and day
10. EBs were dissociated on day 14 by digestion with collagenase B (Roche)
for 2 hr and by treatment with enzyme-free dissociation buffer (GIBCO), then
filtered through an 80 mm filter. Dissociated EBs were frozen in 10% DMSO
and 40% FBS freezing solution.
Lentivirus Production
Plasmids for the 9F library were obtained as Gateway plasmids (Gene-
Copoeia). Open reading frames were cloned into lentiviral vectors using LR
Clonase (Invitrogen). Two vectors were used, pSMAL-GFP (constitutive) and
pINDUCER-21 (Meerbrey et al., 2011). Lentiviral particles were produced by
transfecting 293T-17 cells (ATCC) with the third-generation packaging plas-
mids. Virus was harvested 12 and 36 hr after transfection and concentrated
by ultracentrifugation at 23,000 rpm for 2 hr. Constructs were titered by serial
dilution on 293T cells.
Progenitor Sorting
Dissociated EB cells were thawed following the Lonza Poietics
protocol (http://bio.lonza.com/uploads/tx_mwaxmarketingmaterial/Lonza_
ManualsProductInstructions_Procedure_for_Thawing_Poietics_Cells.pdf) and
resuspended at 1 3 106 per 100 ml staining buffer (PBS + 2% FBS). Cells
were stained with a 1:50 dilution of CD45 PE-Cy5 (Immu19.2; Clontech),
CD34 PE-Cy7 (8G12; BD), and DAPI for 20 min at room temperature. All sort-
ing was performed on a BD FACS Aria II cell sorter using a 70 mm nozzle.
Lentiviral Gene Transfer
Sorted CD34+CD45+ progenitors were seeded on fibronectin-coated
(10 mg/cm2) 96-well plates at a density of 2 to 5 3 104 cells per well. The
infection media was IMDM + 20% BIT (StemCell Technologies), 1 mM
L-glutamine, and 0.1 mM b-mercaptoethanol, with 300 ng/ml SCF, 300 ng/
ml FLT3, 50 ng/ml G- CSF, 20 ng/ml IL6, and 10 ng/ml IL3 (all Peprotech).
Lentiviral infections were carried out in a total volume of 150 ml. The multiplic-
ity of infection for the factors was as follows: 9F 20, ERG 5.0, HOXA9 5.0,
RORA 3.0, SOX4 3.0, and MYB 3.0. Virus was concentrated onto cells by
centrifuging the plate at 2,500 rpm for 30 min at room temperature. Infections
were carried out for 24–36 hr.
Progenitor Culture
Following gene transfer, progenitors were cultured in suspension in infection
media supplemented with 50 ng/ml SCF, 50 ng/ml FLT3, 50 ng/ml TPO,
50 ng/ml IL6, and 10 ng/ml IL3 (all R&D Systems). To standardize these con-
ditions, for all experiments with inducible constructs (including all transplan-
tation experiments), infection media was replaced with StemSpan SFEM
Cell Stem Cell
Respecification of Engraftable Blood Progenitors(StemCell Technologies). Dox was added at 2 mg/ml (Sigma). For culturing on
immobilized ligands, nontissue culture plates were coated with 2.5 mg/ml
Delta1 extIgG and 5 mg/ml recombinant human retronectin (CH296, Takara
Bio) for 2 hr at 37C. Culture media was same as above. Cultures were
maintained at a density of <1 3 106 cells/ml, and media was changed every
3–4 days.
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